Type
Internal restructuring
Country
Sweden
Region
Stockholm; Stockholms län;
Location of affected unit(s)
Södertälje
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.2 - Manufacture of pharmaceutical preparations

1,100 - 1,200 jobs
Number of planned job losses
Job loss
Announcement Date
2 February 2012
Employment effect (start)
2 February 2012
Foreseen end date

Description

Anglo-Swedish pharmaceutical manufacturer AstraZeneca plans to cut between 1100 and 1200 jobs in Södertälje, Sweden, as part of a new restructuring plan. The company plans to cut 7300 jobs worldwide in the third restructuring round since 2007 (see factsheet 19808). Affected by the cuts are mainly researchers, but also medical staff, HR professionals and economists.

As one of the reasons for the restructuring the company gives a gloomy forecast for 2012 with revenue continuing to be adversely affected by competition and government price intervention. AstraZeneca now have plans to create a "virtual" research group in neuroscience, consisting of 40-50 researchers outside Sweden.

The timeline for the restructuring has yet to be announced.


Sources

  • 4 February 2012: Dagens Nyheter
  • 2 February 2012: Dagens Industri
  • 2 February 2012: Svenska Dagbladet

Citation

Eurofound (2012), AstraZeneca, Internal restructuring in Sweden, factsheet number 73050, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/73050.